Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Advances in Therapy|November 25, 2021
Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell LymphomaDivya Samineni, Weize Huang, Leonid Gibiansky, et al.
Journal of Clinical Pharmacology|December 21, 2007
Population pharmacokinetic investigation of actinomycin-D in children and young adultsJohn T Mondick, Leonid Gibiansky, Marc R Gastonguay, et al.
Pharmaceutical Research|May 24, 2011
Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptorTarundeep Kakkar, Cynthia Sung, Leonid Gibiansky, et al.
Clinical and Translational Science|October 21, 2023
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIXMichael Z Liao, Rong Deng, Leonid Gibiansky, et al.
Leukemia & Lymphoma|July 25, 2020
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphomaTong Lu, Leonid Gibiansky, Xiaobin Li, et al.
British Journal of Clinical Pharmacology|August 27, 2021
Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacyEric Burroughs Jordie, Leonid Gibiansky, Timothy Knab, et al.
Translational Vision Science & Technology|November 13, 2024
Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular EdemaCheikh Diack, Robert L Avery, Chui Ming Gemmy Cheung, et al.
Cancer Chemotherapy and Pharmacology|August 10, 2020
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphomaRong Shi, Tong Lu, Grace Ku, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 12, 2015
A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophyKha N Le, Leonid Gibiansky, Jeremy Good, et al.
Advances in Therapy|June 16, 2022
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 TrialDivya Samineni, Leonid Gibiansky, Bei Wang, et al.
Pageof 6